21730-69-8

Usage

InChI:InChI=1/C11H10N2O3/c1-16-9-5-3-2-4-7(9)6-8-10(14)13-11(15)12-8/h2-6H,1H3,(H2,12,13,14,15)/b8-6+

Upstream product

• 461-72-3 2,4-imidazolidinedione 
• 135-02-4 ortho-anisaldehyde 
• 141-43-5 ethanolamine 

Downstream Products

• 101952-26-5 5-(2-methoxy-benzyl)-imidazolidine-2,4-dione 
• 193546-31-5 (S)-2-amino-3-(2-methoxyphenyl)propanoic acid 
• 82204-44-2 Acide o-methoxyphenylpyruvique 
• 334022-78-5 2-hydroxy-3-(2-methoxyphenyl)acrylic acid 
• 861568-54-9 N-carbamoyl-2-methoxy-phenylalanine 

Relevant academic research and scientific papers

Chemoenzymatic synthesis of L-3,4-dimethoxyphenyl-alanine and its analogues using aspartate aminotransferase as a key catalyst

In this study, a chemoenzymatic synthesis method for the production of L-3,4-dimethoxyphenyl-alanine and its analogues from phenylpyruvate derivatives was developed. The aspartate aminotransferase from Escherichia coli was engineered by error prone PCR and the improved variants were identified. When 3, 4-dimethoxy phenylpyruvate was added by fed-batch on a preparative scale, L-3,4-dimethoxyphenyl-alanine was formed in 95.4% conversion and > 99% ee with the best aspartate aminotransferase variant as the catalyst. This study provided an efficient method for the production of methoxy substituted phenylalanines using the engineered aspartate aminotransferase.

Design, synthesis, and biological evaluation of substrate-competitive inhibitors of C-terminal Binding Protein (CtBP)

C-terminal Binding Protein (CtBP) is a transcriptional co-regulator that downregulates the expression of many tumor-suppressor genes. Utilizing a crystal structure of CtBP with its substrate 4-methylthio-2-oxobutyric acid (MTOB) and NAD+ as a guide, we have designed, synthesized, and tested a series of small molecule inhibitors of CtBP. From our first round of compounds, we identified 2-(hydroxyimino)-3-phenylpropanoic acid as a potent CtBP inhibitor (IC50 = 0.24 μM). A structure-activity relationship study of this compound further identified the 4-chloro- (IC50 = 0.18 μM) and 3-chloro- (IC50 = 0.17 μM) analogues as additional potent CtBP inhibitors. Evaluation of the hydroxyimine analogues in a short-term cell growth/viability assay showed that the 4-chloro- and 3-chloro-analogues are 2-fold and 4-fold more potent, respectively, than the MTOB control. A functional cellular assay using a CtBP-specific transcriptional readout revealed that the 4-chloro- and 3-chloro-hydroxyimine analogues were able to block CtBP transcriptional repression activity. This data suggests that substrate-competitive inhibition of CtBP dehydrogenase activity is a potential mechanism to reactivate tumor-suppressor gene expression as a therapeutic strategy for cancer.

Process for the preparation of D1-β-aryl amino acids

The invention relates to a process for the preparation of DL-β-aryl-amino acids of the general Formula STR1 wherein R, R1 and R2 stand for hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, nitro or C1-4 dialkylamino; whereby in the case of monosubstituted derivatives R and R1 are hydrogen and R2 has the same meaning as stated above and can be attached to position 2, 3 or 4 related to the methylene group; in the case of disubstituted derivatives R is hydrogen and R1 and R2 have the same meaning as stated above and are attached to positions 2,3; 2,4; 2,5; 2,6; 3,4 or 3,5 related to the methylene group; in the case of trisubstituted derivatives R, R1 and R2 have the same meaning as stated above and are attached to positions 2,3,4; 2,3,5; 2,3,6; 3,4,5 or 3,4,6 related to the methylene group.

Antiviral 5-(substituted benzal) hydantoins

Therapeutic compositions containing a compound of the formula: STR1 wherein: R1, R2, and R3 are each hydrogen, hydroxy, alkoxyf 1 to 4 carbon atoms, acyloxy of 1 to 4 carbon atoms, halo, or nitro, or R2 and Rsu